Rudic Milan, Wagner Richard, Willkinson Eric, Danese Giovanni, Kiros Nega, Zarkovic Kamelija, Zarkovic Neven
ENT Department, General Hospital Zadar, B. Peričića 5, 23000, Zadar, Croatia,
Eur Arch Otorhinolaryngol. 2015 Oct;272(10):2783-9. doi: 10.1007/s00405-014-3284-z. Epub 2014 Sep 14.
In Ethiopians, like in other Africans, the incidence of otosclerosis is lower than in Western and Asian populations. Unfortunately, due to the lack of available otorhinolaryngology specialists many patients are not treated and suffer the progression of the disease and severe hearing loss. This program of the Global ENT Outreach Organization (GEO) together with the Ethiopian partners was done to help some of these patients and in parallel to evaluate the presence of the oxidative stress bioactive marker 4-hydroxynonenal (HNE), which is known as major lipid peroxidation product and the second messenger of free radicals, in the otosclerotic bone specimens. Namely, we described recently that as HNE acts as a bone growth regulator associated with pathogenesis of otosclerosis. The prospective study conducted at the ENT Department of the Migbare Senay General Hospital, Addis Ababa, Ethiopia in June 2012, under the auspices of the Global ENT Outreach Organization, USA. Altogether 36 patients (male = 12, female = 24) underwent surgery due to the previous otosclerosis diagnosis based on the clinical and audiometric findings. The bone samples were harvested from patients with intraoperatively confirmed otosclerosis diagnosis. Immunohistochemistry for HNE-modified proteins was carried out on formalin-fixed paraffin-embedded specimens. The presence of HNE was found in almost all bone samples analyzed, without particular difference in the HNE distribution pattern between the otosclerotic and respective control bone specimens. Although there was no significant association between the HNE appearance and otosclerotic bone outgrowth observed, several cases have shown tendency of higher HNE expression in patients with more severe hearing loss. The results of the present study are in contrast with our previous findings obtained on European patients most likely due to the differences between studied population groups.
与其他非洲人一样,埃塞俄比亚人的耳硬化症发病率低于西方和亚洲人群。不幸的是,由于缺乏耳鼻喉科专家,许多患者得不到治疗,疾病不断进展,最终导致严重听力损失。全球耳鼻喉科外展组织(GEO)与埃塞俄比亚合作伙伴共同开展了该项目,旨在帮助部分此类患者,同时评估耳硬化骨标本中氧化应激生物活性标志物4-羟基壬烯醛(HNE)的存在情况。HNE是主要的脂质过氧化产物和自由基的第二信使。也就是说,我们最近发现HNE作为一种与耳硬化症发病机制相关的骨生长调节因子发挥作用。2012年6月,在美国全球耳鼻喉科外展组织的支持下,在埃塞俄比亚亚的斯亚贝巴的米加雷·塞纳伊综合医院耳鼻喉科进行了这项前瞻性研究。共有36例患者(男性12例,女性24例)因之前根据临床和听力检查结果确诊为耳硬化症而接受手术。骨样本取自术中确诊为耳硬化症的患者。对福尔马林固定石蜡包埋的标本进行HNE修饰蛋白的免疫组织化学检测。在几乎所有分析的骨样本中均发现了HNE的存在,耳硬化骨标本与相应对照骨标本之间的HNE分布模式没有明显差异。尽管观察到的HNE出现情况与耳硬化骨生长之间没有显著关联,但有几例病例显示,听力损失越严重的患者HNE表达越高。本研究结果与我们之前对欧洲患者的研究结果相反,这很可能是由于研究人群组之间的差异所致。